Navigation Links
Surveyed Experts Indicate That Byetta LAR and Victoza Have Advantages Over Actos in the Treatment of Type 2 Diabetes

Byetta LAR Will Earn Decision Resources' Clinical Gold Standard Status for Type 2 Diabetes in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., March 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed endocrinologists indicate that a therapy's effect on glycosylated hemoglobin A1c (HbA1c) is the attribute that most influences their prescribing decisions in type 2 diabetes. Clinical data and the opinions of interviewed thought leaders indicate that Alkermes/Amylin/Eli Lilly's Byetta LAR and Novo Nordisk's Victoza have advantages in this attribute over Takeda's Actos, the sales-leading agent in the market.

The new report entitled Type 2 Diabetes: Endocrinologists' Satisfaction with Inexpensive Metformin Sets High Hurdles for Emerging Agents finds that a drug that is substantially more effective than metformin (Bristol-Myers Squibb/Merck Serono's Glucophage, generics) at reducing HbA1c and offers improvements in terms of convenience would earn a 33 percent patient share in type 2 diabetes in the United States and a 30 percent patient share in Europe, according to surveyed U.S. and European endocrinologists.

In 2008, Decision Resources' proprietary clinical gold standard for type 2 diabetes was Byetta (exenatide), owing to its efficacy and its propensity to cause weight loss. Based on available data and expert opinion, Byetta LAR will earn gold-standard status for type 2 diabetes in 2012, following its approval for the indication in that year.

"Byetta LAR has competitive advantages in terms of delivery compared with the current gold standard," said Decision Resources Analyst Caroline Gates. "Furthermore, in a 30-week, randomized, open-label clinical trial involving nearly 300 type 2 diabetics, patients treated with Byetta LAR demonstrated statistically significant improvements in glycemic control over patients receiving exenatide."

About the Report

Type 2 Diabetes: Endocrinologists' Satisfaction with Inexpensive Metformin Sets High Hurdles for Emerging Agents is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                           Decision Resources, Inc.
    Christopher Comfort                          Elizabeth Marshall
    781-296-2597                                 781-296-2563            

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with Isentress
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
4. Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology
5. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
6. Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin
7. African Ancestry, Educators, Identity Experts Launch DNA Education Project during Historic Black History Month; 7th Graders Score High on Ultimate Self Test
8. Experts argue nano food-additives require new oversight
9. Top LASIK and Refractive Experts in Trusted LASIK Surgeons Directory Present Research and Educate Their Peers at Annual AAO Meeting in Atlanta
10. BioFlorida Selects Collexis as the Primary Professional Network for its 200 Member Companies and Organizations
11. MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery
Post Your Comments:
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
(Date:11/24/2015)... -- SHPG ) announced today that Jeff Poulton ... th Annual Healthcare Conference in New York City ... EST (1:30 p.m. GMT). --> SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ...
Breaking Biology Technology:
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):